Glutamate Plays Significant Role in Depression

Crenezumab Misses Primary Targets in Phase II Alzheimer's Trial
Crenezumab Misses Primary Targets in Phase II Alzheimer’s Trial
Lower energy production seen in glutamatergic neurons of patients with major depressive disorder.

Emerging evidence suggests that abnormalities in amino acid neurotransmitter function and impaired energy metabolism contribute to the underlying pathophysiology of major depressive disorder.

READ FULL ARTICLE Curated publisher From ajp.psychiatryonline.org